Kestra Advisory Services LLC Has $6.04 Million Stake in Novo Nordisk A/S $NVO

Kestra Advisory Services LLC grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 11.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 164,361 shares of the company’s stock after buying an additional 17,511 shares during the period. Kestra Advisory Services LLC’s holdings in Novo Nordisk A/S were worth $6,040,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. CIBC Bancorp USA Inc. acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at $19,519,000. Romano Brothers AND Company lifted its holdings in Novo Nordisk A/S by 704.0% during the fourth quarter. Romano Brothers AND Company now owns 34,236 shares of the company’s stock worth $1,742,000 after acquiring an additional 29,978 shares in the last quarter. Capital Investment Counsel LLC acquired a new position in Novo Nordisk A/S in the fourth quarter valued at about $3,727,000. Marathon Capital Management grew its stake in Novo Nordisk A/S by 43.9% in the fourth quarter. Marathon Capital Management now owns 82,705 shares of the company’s stock valued at $4,208,000 after acquiring an additional 25,230 shares during the period. Finally, CWA Asset Management Group LLC increased its holdings in shares of Novo Nordisk A/S by 131.9% in the fourth quarter. CWA Asset Management Group LLC now owns 76,993 shares of the company’s stock worth $3,917,000 after acquiring an additional 43,793 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk won EU approval for its once-daily Wegovy pill, making it the first oral GLP-1 weight-loss treatment cleared across the European Union and expanding its obesity market reach. Novo Nordisk wins EU approval for Wegovy weight-loss pill
• Positive Sentiment: Novo Nordisk updated investors on a large Phase 3 heart failure-obesity study, suggesting continued pipeline progress in cardiometabolic disease, a major long-term growth area. Novo Nordisk Expands Cardiometabolic Reach With New Heart Failure–Obesity Trial
• Positive Sentiment: Fresh hemophilia trial results for Mim8/concizumab showed sustained efficacy and safety, expanding evidence for Novo’s rare blood disorder portfolio. Novo Nordisk (CPSE:NOVO B) Reports Fresh Hemophilia Trial Wins In Adults And Children
• Positive Sentiment: Novo Nordisk said most patients are choosing its obesity pill over Eli Lilly’s newer entrant, reinforcing confidence in its competitive position in the weight-loss drug market. It’s been three months since Lilly launched its obesity pill. Most people are taking Novo’s pill instead.
• Neutral Sentiment: Novo Nordisk also signed an agreement to evaluate a semaglutide implant, an early-stage move that adds optionality but is too preliminary to affect near-term results. Novo Nordisk signs pact to assess semaglutide implant
• Negative Sentiment: Sun Pharma won South Africa approval to launch a generic version of semaglutide, highlighting rising competitive pressure on Novo’s diabetes and obesity blockbusters. India’s Sun Pharma wins South Africa approval to launch generic Ozempic
• Negative Sentiment: Zacks Research downgraded Novo Nordisk to “strong sell,” which could weigh on sentiment despite the company’s positive operating news. Novo Nordisk A/S was downgraded by Zacks Research from “hold” to “strong sell”

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $50.56 on Thursday. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $71.79. The company’s fifty day simple moving average is $45.89 and its 200-day simple moving average is $45.80. The firm has a market cap of $225.77 billion, a PE ratio of 11.87, a P/E/G ratio of 4.48 and a beta of 0.77. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The firm had revenue of $10.85 billion for the quarter. Equities research analysts expect that Novo Nordisk A/S will post 3.38 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on NVO. Zacks Research lowered Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research report on Monday. HSBC reissued a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Wolfe Research initiated coverage on shares of Novo Nordisk A/S in a report on Thursday, March 26th. They set a “peer perform” rating on the stock. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, May 12th. Finally, Nordea Equity Research raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Five investment analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.